BFRG BFRG
Company Profile ↓Company Overview
BFRG (BFRG) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 241.6% CAGR over the past five years.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +79.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 241.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 241.57% |
| 1 Year: | 79.49% |
Stock Price Performance
| 1 Year: | -52.23% |
| 6 Months: | +9.52% |
| 3 Months: | -13.99% |
| 1 Month: | -10.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 241.6% over 5 years.
CONS
- Trading 63.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 65.00K | - | - | - | - | 0 | 33.26K | 83.41K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 26.73K | 68.04K | 0 | 0 |
| Gross Profit | - | - | - | - | - | 59.80K | - | - | - | - | 0 | 6.52K | 15.37K | 0 | 0 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 2.06M | 1.48M | 1.59M | 1.50M | 1.61M |
| Operating Income | -550.25K | -681.96K | -640.55K | -1.19M | -1.54M | -1.30M | -1.97M | -1.68M | -1.82M | - | -2.06M | -1.47M | -1.57M | -1.50M | -1.61M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -2.02M | -1.45M | -1.55M | -1.48M | -1.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.01K | 2.45K | 1.54K | 622 | 982 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -2.02M | -1.45M | -1.55M | -1.48M | -1.59M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -566.36K | -775.92K | -764.69K | -1.33M | -1.48M | -1.25M | -1.90M | -1.61M | -1.76M | - | -2.02M | -1.45M | -1.55M | -1.48M | -1.59M |
| Diluted EPS | - | -0.17 | -0.16 | -0.27 | -0.24 | -0.21 | -0.26 | -0.20 | -0.22 | - | -0.21 | -0.15 | -0.15 | - | -0.12 |
| R&D Expense | 316.28K | 92.67K | 39.42K | 369.93K | 273.67K | 380.01K | 552.13K | 513.70K | 566.58K | - | 576.26K | 480.30K | 345.99K | - | 434.82K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 10.00K | 65.00K | - | 116.67K |
| Gross Profit | - | 9.20K | 59.80K | - | 21.89K |
| Operating Income | -555.36K | -2.46M | -5.37M | -7.24M | -6.59M |
| Net Income | -585.84K | -2.80M | -5.36M | -6.99M | -6.50M |
| Diluted EPS | - | -0.70 | -0.89 | -0.85 | -0.63 |
| R&D Expense | 25.00K | 609.27K | 1.43M | 2.22M | 1.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 10.01K | 80.37K | 2.78M | 5.55M | 2.81M |
| Total Equity | -540.52K | -1.01M | -3.06M | 2.59M | 4.96M | 2.14M |
| Cash & Equivalents | - | - | 57.67K | 2.62M | 5.44M | 2.18M |
| Total Liabilities | - | 1.02M | 3.14M | 184.35K | 588.09K | 672.02K |
| Current Liabilities | - | 1.02M | 3.14M | 184.35K | 588.09K | 672.02K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -382.40K | -910.89K | -6.00M | -5.61M | -5.52M |
| Investing Cash Flow | - | -8.74K | - | - | - |
| Financing Cash Flow | 387.40K | 967.29K | 8.57M | 8.42M | 2.37M |
| Capital Expenditure | - | -8.74K | - | - | - |
| Free Cash Flow | - | -919.63K | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 92.0% | 92.0% | - | 18.8% |
| Operating Margin % | - | -24,558.0% | -8,257.7% | - | -5,652.4% |
| Net Margin % | - | -28,024.9% | -8,239.8% | - | -5,569.6% |
| ROE % | 58.1% | 91.7% | -206.6% | -140.9% | -304.2% |
| ROCE % | 55.0% | 80.3% | -207.1% | -145.8% | -308.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BFRG
BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable ins…
BullFrog AI Regains Compliance with Nasdaq Shareholders’ Equity Requirement
Strengthened balance sheet provides capital runway into late 2027GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial …
BullFrog AI Announces Participation at AACR Annual Meeting
BullFrog AI team will be available to discuss its end-to-end drug discovery and development workflow at booth 2957GAITHERSBURG, Md., April 14, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "…
BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder
Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s end-to-end analytical AI platform to accelerate drug discovery and development program GAITHERSBUR…
BullFrog AI Announces New Commercial Leadership Team to Execute Growth Strategy for its Integrated Pharma AI Platform
Seasoned executives with track records of scaling growth and commercial initiatives across enterprise IT solutions, drug discovery and advanced therapy platforms formalize BullFrog AI’s commercial structure to accelerate growth initiativesG…
BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026
GAITHERSBURG, Md., July 21, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using three complementary capabilities to turn complex biomedical data into actionable ins…
BFRG — Frequently Asked Questions
What is the current share price of BFRG?
As of 2026-08-05 17:25 PDT, BFRG trades at $0.62 on NASDAQ/NYSE. Its 52-week range is $0.46 to $1.68.
What is the P/E ratio of BFRG?
BFRG trades at a trailing price-to-earnings (P/E) ratio of -0.98.
Is BFRG a good stock to buy?
This page provides a data-driven analysis of BFRG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.